Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease | [Rawal Medical Journal • 2021]

Author(s):

1. Kashif Rasheed Shaikh: Department of Medicine, Suleman Roshan Medical College, Khairpur Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan

2. Shumaila Shaikh: Department of Medicine, Suleman Roshan Medical College, Khairpur Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan

3. Muhammad Atif Ata: Department of Medicine, Suleman Roshan Medical College, Khairpur Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan

4. Azhar Memon: Department of Medicine, Suleman Roshan Medical College, Khairpur Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan

5. Umair Ali Soomro: Department of Medicine, Suleman Roshan Medical College, Khairpur Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan

6. Shumail Saeed Siddiqui: Department of Medicine, Suleman Roshan Medical College, Khairpur Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan

Abstract:

Objective: To determine the therapeutic efficacy of silymarin on liver aminotransferases in nonalcoholic fatty liver disease (NAFLD). Methodology: This case control study was carried out at Suleman Roshan Medical College from August 2019 to March 2020. A sample of 200 diagnosed cases of NAFLD was divided into 2 groups; cases received 2 tablets silymarin (200 mg) per day for 12 weeks and controls received placebo. Baseline and after 12 weeks blood samples were taken for the liver aminotransferase measurements. Data were analyzed on SPSS version 21.0. Results: Frequency of fatty liver disease at baseline in cases and controls was noted as: grade 1- 32% vs. 31%, grade 2 - 60% vs. 61% and grade 3- 8% vs. 7% (p=0.91. ALT in cases decreased from 89.7±7.31 to 67.3±3.9 IU/mL and AST decreased from 72.3±5.9 to 53.9±5.7 IU/mL while ALT in controls decreased from 88.9±8.1 to 79.3±7.1 and AST from 71.3±5.3 to 70.9±6.13 (p=0.0001). Conclusion: Silymarin therapy effectively improved NAFLD with improvement of liver aminotransferases.

Page(s): 761-764

DOI: DOI not available

Published: Journal: Rawal Medical Journal, Volume: 46, Issue: 4, Year: 2021

Keywords:

sonography , NAFLD , ALT , Silylmarin

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views